Developer docs
API playgroundTry for free, no card

Search company profiles

ExpressionEdits

Full company profile

uuid00022vo

Namestring
ExpressionEdits
Legal namestring
ExpressionEdits Ltd
Company typeenum
Private
Founded yearint
2021
Descriptiontext

ExpressionEdits is a privately held UK biotechnology company founded in 2021 and headquartered in Cambridge, with a registered office in Altrincham. The company has built a computational and experimental platform — the "Genetic Syntax Engine" — that uses AI and deep biological insights to redesign synthetic DNA (transgenes) for enhanced protein expression across therapeutic modalities. Its core proprietary method, "intronization," enables the integration of very small introns (as small as 80 base pairs) into gene constructs to boost expression without exceeding vector size constraints, addressing a class of difficult-to-express therapeutic proteins that conventional codon optimization and strong viral promoters cannot solve.

The platform is built around a paired wet-lab and dry-lab organization: computational teams led by CTO Dr. Leopold Parts develop AI models for transgene prediction and optimization, while experimental teams across RNA technologies, protein technologies, vector technologies, and translational biology generate the proprietary datasets that train and validate those models. ExpressionEdits pursues a dual business model combining (a) a partnership-led GTM motion targeting pharmaceutical and biotechnology companies — exemplified by a February 2025 collaboration with Boehringer Ingelheim to develop enhanced gene therapies — with (b) an internal pipeline of recombinant protein therapeutics, initiated under CSO Dr. Amrik Basran (appointed March 2025). Revenue is derived from custom co-development agreements, research collaborations, and potential milestone payments and royalties.

The company has raised approximately $13M in seed funding (May 2024) from a syndicate led by Octopus Ventures and redalpine, with participation from Acequia Capital, Amino Collective, BlueYard Capital, Hawktail Management, and Wilbe. It has grown to a team of approximately 17 people, anchored scientifically by co-founder Prof. Allan Bradley (Royal Society Fellow, genome engineering pioneer and founder of Kymab, acquired by Sanofi) and operationally led by CEO Dr. Kärt Tomberg, COO Dr. Rebecca Godfrey (former AbbVie, Roche), and Chair Dr. Paul Bolno (CEO of Wave Life Sciences).

Short descriptiontext

ExpressionEdits is a Cambridge, UK-based biotechnology company that uses an AI-driven "Genetic Syntax Engine" combined with proprietary intronization technology to redesign synthetic DNA for enhanced protein expression, serving pharmaceutical and biotechnology partners and advancing an internal pipeline of previously infeasible therapeutic proteins.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersCambridge, United Kingdom
HQ citystring
Cambridge
HQ countrystring
United Kingdom
HQ regionstring
Europe
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
protein expression optimization, transgene design platform, gene therapy development, AI drug discovery, biotechnology platform
Industry4 codes
PRIMARYHLAAAIAC
Protein Engineering & Directed Evolution Platforms (enzyme/therapeutic protein optimization)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAAAAAB
Recombinant Protein Therapeutics (enzymes, hormones, growth factors)
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)
SECONDARYHLAAAAAJ
Engineered Protein Therapeutics (de novo/AI-designed proteins, novel scaffolds)
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)
SECONDARYHLAAACAI
Cardiometabolic & Other Systemic Gene Therapies
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)
NAICS code1 code
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code1 code
  • Biological Products, (No Disgnostic Substances)2836
Product category
Computational Biology Platform
Social media profiles2 records
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Strategic Partnerships and Collaborations
TypeLicensing Royalties
Description

ExpressionEdits generates revenue through strategic co-development partnerships with pharmaceutical and biotechnology companies. The company collaborates on developing enhanced gene therapies and therapeutic proteins using their proprietary Genetic Syntax Engine. Revenue is derived from partnership agreements, research collaborations, and potentially milestone payments and royalties from successful therapeutic development.

expressionedits.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure
GTM typeB2B
B2B
Offering typeSoftware
Software
Core offering1 text field

ExpressionEdits develops an AI-driven computational platform called the Genetic Syntax Engine that predicts transgene performance and redesigns synthetic DNA sequences to enhance protein expression. Combined with its proprietary intronization technology—which integrates small introns (as small as 80 base pairs) into gene constructs—the company enables the production of therapeutic proteins previously considered infeasible and supports gene therapy optimization across therapeutic modalities.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 2 values shown
  • Expression of proteins previously beyond reach using conventional methods
+1 more record
Product overview1 text field

ExpressionEdits offers a unified platform combining the Genetic Syntax Engine (a computational AI-driven platform) with proprietary intronization technology to enhance protein expression. The Genetic Syntax Engine serves as the core computational platform that uses AI and deep biological insights to predict performance and redesign transgenes, while the intronization technology provides the biological mechanism (strategic intron integration) to achieve enhanced expression. Together, these enable the company to overcome production challenges in therapeutic protein manufacturing and gene therapy applications.

Product and service2 records
1Genetic Syntax Engine
CategoryCore platform
Description

AI-driven computational platform that perfects genetic grammar by predicting transgene performance and redesigning genetic sequences to unlock protein expression across therapeutic modalities, including gene therapies and recombinant proteins. Targeted at pharmaceutical and biotechnology R&D teams.

2Intronization Technology
CategoryCore platform
Description

Proprietary method for enhancing gene expression by integrating small introns (as small as 80 base pairs, versus a typical intron size of over 1,500 base pairs) into genetic constructs, enabling production of proteins previously beyond reach using conventional methods. Targeted at therapeutic protein and gene therapy developers.

Scale indicator2 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
1Boehringer Ingelheim
Strategic tierFlagshipTypeStrategic or Co-development PartnerAnnounced on2025-02-01
Description

ExpressionEdits collaborates with Boehringer Ingelheim to develop enhanced gene therapies using the Genetic Syntax Engine platform. The collaboration aims to boost gene therapy potency and precision without altering core designs through optimal site and intron integration in circular intron RNAs (in-cRNAs).

expressionedits.com
Recent move5 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

AI-driven platform for RNA biology and oligonucleotide therapeutics discovery, including target identification and RNA-targeted drug design. Directly comparable as an AI platform company optimizing nucleic-acid-based therapeutics for pharma partners.

TypeDirect peer
Description

Applies AI/ML to AAV capsid engineering for gene therapy, optimizing delivery vehicles for partners including Novartis and Roche. Highly comparable as an AI platform serving gene therapy developers via pharma partnerships.

TypeDirect peer
Description

Generative AI platform for novel protein therapeutics design. Comparable as an AI-first biotech building both a partnership platform and an internal protein therapeutics pipeline, similar in strategy to ExpressionEdits.

TypeDirect peer
Description

Machine learning platform for protein engineering, enabling partners to design improved proteins faster. Directly comparable as an AI/ML protein optimization platform serving biotech and pharma customers.

TypeEmerging player
Description

Gene writing technology platform that designs and writes therapeutic genetic sequences. Adjacent as a platform rewriting or designing genetic code for therapeutic applications, with overlapping target customers in gene therapy.

TypeDirect peer
Description

Synthetic biology platform using AI and genetic engineering tools to design mammalian cell systems and genetic constructs for therapeutic protein and gene therapy production. Comparable as an AI-driven platform optimizing transgene and expression system design.

TypeBroad incumbent
Description

Clinical-stage RNA medicines company developing stereopure oligonucleotides. Comparable as a nucleic-acid-based therapeutics platform; Dr. Paul Bolno (ExpressionEdits Chair) is Wave's CEO, providing a direct linkage.

TypeEmerging player
Description

Platform for digital genome engineering, providing tools for writing and editing DNA at scale. Adjacent in providing infrastructure for optimizing genetic constructs for protein expression applications.

TypeBroad incumbent
Description

Clinical-stage gene therapy company with proprietary AAV vector discovery platform (Therapeutic Vector Evolution). Comparable as a gene therapy platform using engineered genetic constructs to improve therapeutic performance.

TypeBroad incumbent
Description

Major mRNA therapeutics and gene therapy company with proprietary platforms for nucleic acid design and protein expression. Comparable as a large incumbent pursuing AI/ML-enhanced nucleic acid and protein therapeutics design.

Market position
Strengths1 record

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers1 record

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability3 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature2 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles10 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance2 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds2 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors7 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

ExpressionEdits

Computational Biology Platformexpressionedits.com

ExpressionEdits is a Cambridge, UK-based biotechnology company that uses an AI-driven "Genetic Syntax Engine" combined with proprietary intronization technology to redesign synthetic DNA for enhanced protein expression, serving pharmaceutical and biotechnology partners and advancing an internal pipeline of previously infeasible therapeutic proteins.

What ExpressionEdits does

ExpressionEdits is a privately held UK biotechnology company founded in 2021 and headquartered in Cambridge, with a registered office in Altrincham. The company has built a computational and experimental platform — the "Genetic Syntax Engine" — that uses AI and deep biological insights to redesign synthetic DNA (transgenes) for enhanced protein expression across therapeutic modalities. Its core proprietary method, "intronization," enables the integration of very small introns (as small as 80 base pairs) into gene constructs to boost expression without exceeding vector size constraints, addressing a class of difficult-to-express therapeutic proteins that conventional codon optimization and strong viral promoters cannot solve.

The platform is built around a paired wet-lab and dry-lab organization: computational teams led by CTO Dr. Leopold Parts develop AI models for transgene prediction and optimization, while experimental teams across RNA technologies, protein technologies, vector technologies, and translational biology generate the proprietary datasets that train and validate those models. ExpressionEdits pursues a dual business model combining (a) a partnership-led GTM motion targeting pharmaceutical and biotechnology companies — exemplified by a February 2025 collaboration with Boehringer Ingelheim to develop enhanced gene therapies — with (b) an internal pipeline of recombinant protein therapeutics, initiated under CSO Dr. Amrik Basran (appointed March 2025). Revenue is derived from custom co-development agreements, research collaborations, and potential milestone payments and royalties.

The company has raised approximately $13M in seed funding (May 2024) from a syndicate led by Octopus Ventures and redalpine, with participation from Acequia Capital, Amino Collective, BlueYard Capital, Hawktail Management, and Wilbe. It has grown to a team of approximately 17 people, anchored scientifically by co-founder Prof. Allan Bradley (Royal Society Fellow, genome engineering pioneer and founder of Kymab, acquired by Sanofi) and operationally led by CEO Dr. Kärt Tomberg, COO Dr. Rebecca Godfrey (former AbbVie, Roche), and Chair Dr. Paul Bolno (CEO of Wave Life Sciences).

ExpressionEdits firmographics

Firmographics
Name
ExpressionEdits
Legal name
ExpressionEdits Ltd
Website
https://expressionedits.com
Company type
Private
Founded year
2021
Operating status
Operating
Headcount range
11–50 employees
Short description
ExpressionEdits is a Cambridge, UK-based biotechnology company that uses an AI-driven "Genetic Syntax Engine" combined with proprietary intronization technology to redesign synthetic DNA for enhanced protein expression, serving pharmaceutical and biotechnology partners and advancing an internal pipeline of previously infeasible therapeutic proteins.
Ownership category
akta.pro rank

ExpressionEdits industry classification

Industry
Product category
Computational Biology Platform
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYHLAAAIAC
Protein Engineering & Directed Evolution Platforms (enzyme/therapeutic protein optimization)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAAAAAB
Recombinant Protein Therapeutics (enzymes, hormones, growth factors)
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)
SECONDARYHLAAAAAJ
Engineered Protein Therapeutics (de novo/AI-designed proteins, novel scaffolds)
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)
SECONDARYHLAAACAI
Cardiometabolic & Other Systemic Gene Therapies
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)

Keywords

  • Protein expression optimization
  • Transgene design platform
  • Gene therapy development
  • AI drug discovery
  • Biotechnology platform

Where ExpressionEdits is headquartered

Location

Headquarters

HQ city
Cambridge
HQ country
United Kingdom
HQ region
Europe

Offices2 records

Markets served

ExpressionEdits business model

Business model
GTM type
B2B
Offering type
Software
Cost components
Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure

Revenue model

  1. Strategic Partnerships and Collaborations: ExpressionEdits generates revenue through strategic co-development partnerships with pharmaceutical and biotechnology companies. The company collaborates on developing enhanced gene therapies and therapeutic proteins using their proprietary Genetic Syntax Engine. Revenue is derived from partnership agreements, research collaborations, and potentially milestone payments and royalties from successful therapeutic development.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

ExpressionEdits product offering

Product offering

Core offering

ExpressionEdits develops an AI-driven computational platform called the Genetic Syntax Engine that predicts transgene performance and redesigns synthetic DNA sequences to enhance protein expression. Combined with its proprietary intronization technology—which integrates small introns (as small as 80 base pairs) into gene constructs—the company enables the production of therapeutic proteins previously considered infeasible and supports gene therapy optimization across therapeutic modalities.

Product overview

ExpressionEdits offers a unified platform combining the Genetic Syntax Engine (a computational AI-driven platform) with proprietary intronization technology to enhance protein expression. The Genetic Syntax Engine serves as the core computational platform that uses AI and deep biological insights to predict performance and redesign transgenes, while the intronization technology provides the biological mechanism (strategic intron integration) to achieve enhanced expression. Together, these enable the company to overcome production challenges in therapeutic protein manufacturing and gene therapy applications.

Differentiator

Problem solved

Functional benefit

Products and services

  • Genetic Syntax Engine AI-driven computational platform that perfects genetic grammar by predicting transgene performance and redesigning genetic sequences to unlock protein expression across therapeutic modalities, including gene therapies and recombinant proteins. Targeted at pharmaceutical and biotechnology R&D teams.
  • Intronization Technology Proprietary method for enhancing gene expression by integrating small introns (as small as 80 base pairs, versus a typical intron size of over 1,500 base pairs) into genetic constructs, enabling production of proteins previously beyond reach using conventional methods. Targeted at therapeutic protein and gene therapy developers.

Quantifiable outcome

  • Expression of proteins previously beyond reach using conventional methods
  • +1 more outcomes

Companies that use ExpressionEdits

Customer profile

Named customers1 record

Segments1 record

Ideal customer profiles1 record

ExpressionEdits technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability3 records

Feature2 records

ExpressionEdits partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • Boehringer IngelheimflagshipStrategic or Co-development Partner · 1 February 2025ExpressionEdits collaborates with Boehringer Ingelheim to develop enhanced gene therapies using the Genetic Syntax Engine platform. The collaboration aims to boost gene therapy potency and precision without altering core designs through optimal site and intron integration in circular intron RNAs (in-cRNAs).

Scale indicators2 records

Recent moves5 records

Expansion highlights5 records

ExpressionEdits competitors and assessment

Company assessment

Direct peers

  • Deep Genomics: AI-driven platform for RNA biology and oligonucleotide therapeutics discovery, including target identification and RNA-targeted drug design. Directly comparable as an AI platform company optimizing nucleic-acid-based therapeutics for pharma partners.
  • Dyno Therapeutics: Applies AI/ML to AAV capsid engineering for gene therapy, optimizing delivery vehicles for partners including Novartis and Roche. Highly comparable as an AI platform serving gene therapy developers via pharma partnerships.
  • Generate Biomedicines: Generative AI platform for novel protein therapeutics design. Comparable as an AI-first biotech building both a partnership platform and an internal protein therapeutics pipeline, similar in strategy to ExpressionEdits.
  • Cradle Bio: Machine learning platform for protein engineering, enabling partners to design improved proteins faster. Directly comparable as an AI/ML protein optimization platform serving biotech and pharma customers.
  • Asimov: Synthetic biology platform using AI and genetic engineering tools to design mammalian cell systems and genetic constructs for therapeutic protein and gene therapy production. Comparable as an AI-driven platform optimizing transgene and expression system design.

Emerging players

  • Tessera Therapeutics: Gene writing technology platform that designs and writes therapeutic genetic sequences. Adjacent as a platform rewriting or designing genetic code for therapeutic applications, with overlapping target customers in gene therapy.
  • Inscripta (now Telesis Bio): Platform for digital genome engineering, providing tools for writing and editing DNA at scale. Adjacent in providing infrastructure for optimizing genetic constructs for protein expression applications.

Broad incumbents

  • Wave Life Sciences: Clinical-stage RNA medicines company developing stereopure oligonucleotides. Comparable as a nucleic-acid-based therapeutics platform; Dr. Paul Bolno (ExpressionEdits Chair) is Wave's CEO, providing a direct linkage.
  • 4D Molecular Therapeutics: Clinical-stage gene therapy company with proprietary AAV vector discovery platform (Therapeutic Vector Evolution). Comparable as a gene therapy platform using engineered genetic constructs to improve therapeutic performance.
  • BioNTech: Major mRNA therapeutics and gene therapy company with proprietary platforms for nucleic acid design and protein expression. Comparable as a large incumbent pursuing AI/ML-enhanced nucleic acid and protein therapeutics design.

Market position

Strengths1 record

Weaknesses5 records

Competitive moat3 records

Key risks6 records

Key highlights6 records

Customer concentration

ExpressionEdits social profiles

Digital presence

ExpressionEdits compliance and trust

Trust signal

Compliance2 records

ExpressionEdits financial estimates

Financial estimate

Revenue estimate

Valuation estimate

ExpressionEdits leadership team

Management profile

Number of profiles

Profiles10 records

ExpressionEdits funding detail

Funding detail

Funding overview

Funding rounds2 records

Investors7 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

ExpressionEdits M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about ExpressionEdits

What does ExpressionEdits do?

ExpressionEdits develops an AI-driven computational platform called the Genetic Syntax Engine that predicts transgene performance and redesigns synthetic DNA sequences to enhance protein expression. Combined with its proprietary intronization technology—which integrates small introns (as small as 80 base pairs) into gene constructs—the company enables the production of therapeutic proteins previously considered infeasible and supports gene therapy optimization across therapeutic modalities.

Is ExpressionEdits a public or private company?

ExpressionEdits is a private company. It is classified as venture growth investor backed and is currently operating.

When was ExpressionEdits founded?

ExpressionEdits was founded in 2021. It employs 11 to 50 people.

Where is ExpressionEdits based?

ExpressionEdits is headquartered in Cambridge, United Kingdom, in the Europe region.

How does ExpressionEdits make money?

One revenue line is on record: strategic Partnerships and Collaborations.

Who are ExpressionEdits's main competitors?

Direct peers on record are Deep Genomics, Dyno Therapeutics, Generate Biomedicines, Cradle Bio and Asimov. Emerging players are Tessera Therapeutics and Inscripta (now Telesis Bio). Broad incumbents are Wave Life Sciences, 4D Molecular Therapeutics and BioNTech.

Does ExpressionEdits have an API?

No public API is recorded for ExpressionEdits.

What industry is ExpressionEdits in?

ExpressionEdits's product category is Computational Biology Platform. Its primary akta.pro industry code is HLAAAIAC, Protein Engineering & Directed Evolution Platforms (enzyme/therapeutic protein optimization), with a secondary code of HLAAAAAB, Recombinant Protein Therapeutics (enzymes, hormones, growth factors). Its NAICS code is 541714 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
BusinessCloudWhat does Cambridge need to produce the next unicorns?Cambridge tech founders and business leaders discussed the city's path to producing the next unicorns, noting its 150,000 residents have spawned nearly 30% of the UK's 97 unicorns. They highlighted funding gaps, infrastructure needs, and the need to look beyond Cambridge for capital, while praising the ecosystem's trust and passion.FirstWordPharma Industry News and AnalysisBoehringer Ingelheim has entered a partnership with South Korean biotech Galux to utilize GaluxDesign for AI-driven protein design research. This agreement is the third such AI collaboration for Boehringer this year, following deals with ExpressionEdits and Tempus AI to enhance its drug discovery capabilities.GenengnewsExpressionEdits Partners with Boehringer to Enhance Gene Therapies with AI-Based Intron DesignExpressionEdits has entered into a licensing and collaboration agreement with Boehringer Ingelheim to utilize its AI-powered Genetic Syntax Engine for enhancing gene therapies. This partnership leverages the company's proprietary intron design technology, which significantly boosts protein expression without altering underlying genetic sequences. ExpressionEdits intends to partner with larger pharmaceutical firms to advance these candidates through development.BusinessCloudLeading European VC to open London base alongside $200m fundredalpine, a European VC firm, will open a London base and launched its seventh fund, RAC VII, at $200 million, its largest to date. The fund has invested in nine companies, including UK-based Expression Edits, and the firm's total assets under management exceed $1 billion.BusinessCloudCambridge spinout raises £10.2m ‘to revolutionise gene design’ExpressionEdits, a Cambridge spinout, raised £10.2m in seed funding co-led by Octopus Ventures and redalpine. The company uses intronisation technology to improve gene expression and protein production. The funds will accelerate preclinical candidate selection and develop a pipeline of protein-based therapeutics.Analytics InsightExpressionEdits Raises $13M Funding for Protein ExpressionBiotechnology company ExpressionEdits secured $13 million in seed funding led by Octopus Ventures and Red Alpine to advance its AI-driven protein expression technology. The investment will accelerate candidate selection for preclinical research and the development of a pipeline focused on recombinant proteins. This funding aims to address historical manufacturing challenges in producing therapeutic proteins through the company's proprietary intronization technology.GoodwinlawExpressionEdits Raises $13 Million in Seed FundingExpressionEdits secured $13 million in seed funding for its proprietary intronization technology, which enhances gene expression and protein production. The round was co-led by Octopus Ventures and redalpine, with participation from BlueYard Capital, Wilbe Capital, Acequia Capital, Amino Collective, and Hawktail.FinSMEsExpressionEdits Raises $13M in Seed FundingExpressionEdits, a Cambridge-based biotech, raised $13M in seed funding led by Octopus Ventures and redalpine. The company will use the funds to accelerate candidate selection for preclinical studies and develop a pipeline of protein-based therapeutics.TmcnetExpressionEdits Raises $13M in Seed Funding to Advance Protein Expression Using AI-Driven Intronization TechnologyExpressionEdits raised $13 million in seed funding co-led by Octopus Ventures and redalpine. The biotech company uses AI-driven intronization technology to improve protein expression, aiming to develop a pipeline of protein-based therapeutics. The funding will accelerate candidate selection for preclinical studies.MorningstarExpressionEdits Raises $13M in Seed Funding to Advance Protein Expression Using AI-Driven Intronization TechnologyExpressionEdits raised $13 million in seed funding co-led by Octopus Ventures and redalpine. The company's AI-driven intronization technology improves protein expression, and the funds will accelerate preclinical candidate selection and pipeline development.